I suspect the main cause of lower profits was the GFC, as well as the ongoing healthcare issues in the US. Post GFC sales dropped, and it was only about march last year that the Obama health reforms began. Add to that the CPT category 3 reimbursement being awarded last year, I think the worst is over.
Add to that, academia has only in the last decade began to realise the important of core blood pressure vs brachial (arm). Atcor is the gold standard reference in hundreds (?) of papers. Clinicians are beginning to see value, starting with the specialists.
Given time, there's good potential (2 bn market). http://www.atcormedical.com/pdf/news_221012.pdf
I challenge anyone to find a company with revenue, on the verge of profitability, with a market cap this size, in a potential market of that size. Potential hundred bagger imo (assuming no further dilution).
If only they released a mobile app / device for core blood.
ACG Price at posting:
8.2¢ Sentiment: LT Buy Disclosure: Held
